Parkinson's disease-like symptom relief
β-NMN addresses the challenge of mitochondrial dysfunction in Parkinson's disease by safely alleviating symptoms and enhancing mitochondrial function, effectively reducing motor dysfunction and creatine kinase levels.
Patent Information
- Application Number
- JP2020203345
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2020-12-08
- Publication Date
- 2024-11-13
- Estimated Expiration
- 2040-12-08
AI Technical Summary
Current treatments for Parkinson's disease do not effectively alleviate symptoms associated with mitochondrial dysfunction, which are a key contributor to the disease's progression.
A composition containing β-NMN as an active ingredient, which can be safely ingested, is developed to alleviate Parkinson's disease-like symptoms by improving mitochondrial function.
β-NMN effectively alleviates Parkinson's disease-like motor dysfunction and suppresses the increase in blood creatine kinase levels, indicating improved mitochondrial function and reduced symptom severity.
Smart Images

Figure 0007582854000003 
Figure 0007582854000004 
Figure 0007582854000005
Abstract
Description
[Technical field]
[0001] The present invention relates to a material that can be safely ingested and is capable of alleviating the symptoms of Parkinson's disease, and to an agent for alleviating Parkinson's disease-like symptoms that contains said material as an active ingredient. [Background technology]
[0002] Parkinson's disease is a progressive neurodegenerative disease in which abnormalities in the brain cause motor dysfunction. The main pathology is a decrease in dopamine neurons in the substantia nigra, leading to a lack of dopamine. Reported reasons for the decrease in dopamine neurons include the accumulation of abnormal proteins, oxidative stress, mitochondrial dysfunction, inflammation, and apoptosis.
[0003] Rotenone, a chemical used as a pesticide or insecticide, has the effect of inhibiting the electron transport chain in mitochondria. It has been reported that administration of rotenone to experimental animals such as rats can induce Parkinson's disease-like motor dysfunction and brain pathology, suggesting that Parkinson's disease is caused by mitochondrial abnormalities.
[0004] β-nicotinamide mononucleotide (hereinafter sometimes referred to as "β-NMN") is a coenzyme NAD + It is an intermediate metabolic product in the biosynthesis of β-NMN. In recent years, it has been reported that β-NMN has the effect of improving insulin secretion in aged mice, the effect of dramatically improving insulin sensitivity and secretion in mouse models of type 2 diabetes caused by a high-fat diet and aging (see, for example, Patent Document 1), the effect of being involved in the control of circadian rhythms (see, for example, Patent Document 2), and the effect of significantly enhancing mitochondrial function in aged muscles. Furthermore, it has been reported that administration of β-NMN is useful for improving and preventing the symptoms of various diseases associated with aging, such as obesity, elevated blood lipid levels, decreased insulin sensitivity, memory loss, and deterioration of eye function such as macular degeneration (see, for example, Patent Document 3). Furthermore, administration of β-NMN increases NAD in the body. +By increasing the amount of NMN and activating the sirtuin gene, it is expected that the decline in physical functions associated with aging in the body can be suppressed and delayed, resulting in anti-aging effects (see, for example, Patent Document 4). Recently, clinical trials have been conducted in which NMN was orally administered to humans, and it has been confirmed that there are no safety issues (see, for example, Non-Patent Document 1). [Prior art documents] [Patent documents]
[0005] [Patent Document 1] U.S. Patent No. 7,737,158 [Patent Document 2] US Patent Application Publication No. 2011 / 123510 [Patent Document 3] International Publication No. 2014 / 146044 [Patent Document 4] International Publication No. 2017 / 200050 [Non-patent literature]
[0006] [Non-Patent Document 1] Irie J et al., “Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men.”, Endocr J, Vol. 67, No. 2, pp. 153-160, 2020. Summary of the Invention [Problem to be solved by the invention]
[0007] An object of the present invention is to provide a material that can be safely ingested and has the effect of alleviating Parkinson's disease-like symptoms. [Means for solving the problem]
[0008] As a result of intensive research aimed at solving the above problems, the present inventors discovered that β-NMN has the effect of alleviating Parkinson's disease-like symptoms, and thus completed the present invention.
[0009] That is, the present invention provides the following agents for alleviating Parkinson's disease-like symptoms, dietary supplements, and feeds. [1] An agent for alleviating Parkinson's disease-like symptoms, comprising as an active ingredient one selected from β-NMN, its pharmacologically acceptable salts, and solvates thereof. [2] A symptom-relieving agent as described in [1] above, which is administered orally. [3] The symptom-relieving agent according to [1] or [2] above, which alleviates Parkinson's disease-like motor dysfunction caused by mitochondrial dysfunction. [4] A dietary supplement for relieving Parkinson's disease-like symptoms, containing any of the symptom-relieving agents [1] to [3]. [5] Feed for alleviating Parkinson's disease-like symptoms, containing any of the symptom-alleviating agents [1] to [3]. Effect of the Invention
[0010] The Parkinson's disease-like symptom alleviating agent according to the present invention contains β-NMN, which is naturally present in the body, as an active ingredient and can alleviate Parkinson's disease-like motor dysfunction. Therefore, the Parkinson's disease-like symptom alleviating agent according to the present invention can be safely ingested without causing side effects and is effective in preventing and alleviating diseases caused by decreased function of mitochondria in the brain. [Brief description of the drawings]
[0011] [Figure 1] 1 is a graph showing the survival rates of β-NMN-added groups (5, 50, 500 μmol / L (μM)) and a β-NMN-not-added group under rotenone-added conditions in Example 1. [Diagram 2] 1 is a graph showing the survival rates of a β-NMN-added group and a β-NMN-non-added group under 6-hydroxydopamine (6-OHDA)-added conditions in Example 2. [Diagram 3] 1 is a graph showing the survival rates of a non-addition group, a rotenone-addition group, a rotenone and edaravone-addition group, and a rotenone, edaravone and β-NMN-addition group in Example 3. [Figure 4] FIG. 13 is a graph showing the NAD concentration content (pmol / mg blood cells) in blood cells of rats in the group administered with water only (non-administration group), the group administered with rotenone, and the group administered with rotenone and β-NMN (rotenone+NMN administration group) in Example 4. [Diagram 5] FIG. 13 is a graph showing the results (sec) of coordinated movement measurement for each of rats in the group administered with water only (non-administration group), the group administered with rotenone (rotenone administration group), and the group administered with rotenone and β-NMN (rotenone+NMN administration group) in Example 4. [Figure 6] 13 shows the results of Example 4 showing the correlation between the NAD content in blood cells and the results of the coordination test under rotenone administration conditions. [Figure 7] FIG. 13 is a graph showing the measurement results (U / L) of creatine kinase in plasma of rats in a group administered with water only (non-administration group), a group administered with rotenone (rotenone administration group), and a group administered with rotenone and β-NMN (rotenone + NMN administration group) in Example 4. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0012] The Parkinson's disease-like symptom-relieving agent according to the present invention (hereinafter, sometimes referred to as the "symptom-relieving agent according to the present invention") is NMN (chemical formula: C 11 H 15 N 2 O 8P) as an active ingredient, and has the effect of alleviating Parkinson's disease-like motor dysfunction. Therefore, the symptom-relieving agent of the present invention is suitable as an active ingredient of an oral composition or an external composition for preventing or alleviating symptoms caused by Parkinson's disease. In addition, Parkinson's disease-like motor dysfunction here includes, for example, resting tremor, akinesia, muscle rigidity, impaired postural reflexes, impaired gait, freezing of gait, impaired swallowing, abnormal posture, etc. As shown in the examples below, by orally administering NMN to Parkinson's disease model animals injected with rotenone into the substantia nigra, motor dysfunction is improved and the increase in blood creatine kinase concentration is also suppressed. As shown by this result, the symptom-relieving agent of the present invention can particularly alleviate Parkinson's disease-like motor dysfunction caused by mitochondrial dysfunction. In addition, the symptom-relieving agent of the present invention is also useful as an agent for suppressing the increase in blood creatine kinase level caused by mitochondrial dysfunction.
[0013] NMN has two optical isomers, α and β, but the NMN that is the active ingredient of the symptom-relieving agent of the present invention is β-NMN (CAS number: 1094-61-7). The structure of β-NMN is shown below.
[0014] [ka]
[0015] The β-NMN used as an active ingredient may be prepared by any method. For example, β-NMN artificially synthesized by chemical synthesis, enzymatic method, fermentation method, etc., and purified β-NMN can be used as an active ingredient. In addition, since β-NMN is a component that is widely present in living organisms, β-NMN obtained by extraction and purification from natural raw materials such as animals, plants, and microorganisms can also be used as an active ingredient. Commercially available purified β-NMN may also be used.
[0016] As a chemical synthesis method for synthesizing β-NMN, for example, NAM can be reacted with L-ribose tetraacetate and the resulting nicotinamide mononucleoside can be phosphorylated to produce β-NMN. As an enzymatic method, for example, β-NMN can be produced from NAM and 5'-phosphoribosyl-1'-pyrophosphate (PRPP) using nicotinamide phosphoribosyltransferase (NAMPT). As a fermentation method, for example, β-NMN can be produced from NAM using the metabolic system of a microorganism expressing NAMPT.
[0017] The active ingredient of the symptom-relieving agent according to the present invention may be a pharmacologically acceptable salt of β-NMN. The pharmacologically acceptable salt of β-NMN may be an inorganic acid salt or an organic acid salt having a basic site such as an amine. Examples of acids constituting such acid salts include acetic acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, citric acid, ethenesulfonic acid, fumaric acid, gluconic acid, glutamic acid, hydrobromic acid, hydrochloric acid, isethionic acid, lactic acid, maleic acid, malic acid, mandelic acid, methanesulfonic acid, mucic acid, nitric acid, pamoic acid, pantothenic acid, phosphoric acid, succinic acid, sulfuric acid, tartaric acid, and p-toluenesulfonic acid. The pharmacologically acceptable salt of β-NMN may be an alkali salt or an organic salt having an acidic site such as a carboxylic acid. Examples of bases that constitute such acid salts include alkali metal salts or alkaline earth metal salts, such as those derived from bases such as sodium hydride, potassium hydroxide, calcium hydroxide, aluminum hydroxide, lithium hydroxide, magnesium hydroxide, zinc hydroxide, ammonia, trimethylammonia, triethylammonia, ethylenediamine, lysine, arginine, ornithine, choline, N,N'-dibenzylethylenediamine, chloroprocaine, procaine, diethanolamine, N-benzylphenethylamine, diethylamine, piperazine, tris(hydroxymethyl)-aminomethane, and tetramethylammonium hydroxide.
[0018] The active ingredient of the symptom-relieving agent of the present invention may be a solvate of free β-NMN or a solvate of a pharmacologically acceptable salt of β-NMN. Solvents that form the solvate include water, ethanol, etc.
[0019] The symptom-relieving agent according to the present invention may contain other active ingredients in addition to β-NMN. The other active ingredients are not particularly limited as long as they do not impair the effect of β-NMN in alleviating Parkinson's disease-like symptoms. Examples of the other active ingredients include functional materials other than β-NMN that have a known effect of alleviating Parkinson's disease-like symptoms. Examples of functional materials that have a known effect of alleviating Parkinson's disease-like symptoms include amino acids such as phenylalanine and tyrosine, and vitamin D.
[0020] The symptom-relieving agent according to the present invention may be composed of only the active ingredient, or may contain other ingredients. For example, the symptom-relieving agent according to the present invention can be formulated into various dosage forms by combining the active ingredient with a non-toxic pharmaceutical carrier by conventional means in formulation. Among the dosage forms of the symptom-relieving agent according to the present invention, examples of oral administration agents include solid agents such as tablets, granules, powders, capsules, and soft capsules; liquid agents such as solutions, suspensions, and emulsions; and freeze-dried preparations. Examples of parenteral administration agents include injections, suppositories, sprays, transdermal absorption agents, and the like.
[0021] Examples of non-toxic pharmaceutical carriers used in formulation include sugars such as glucose, lactose, sucrose, fructose, reduced maltose, etc.; carbohydrates such as starch, hydroxyethyl starch, dextrin, β-cyclodextrin, crystalline cellulose, hydroxypropyl cellulose, etc.; sugar alcohols such as mannitol, erythritol, sorbitol, xylitol, etc.; esters such as fatty acid glycerides and polyoxyethylene sorbitan fatty acid esters, etc.; polyethylene glycol, ethylene glycol, amino acids, albumin, casein, silicon dioxide, water, physiological saline, etc. In addition, in formulating the symptom-relieving agent according to the present invention, conventional additives such as stabilizers, lubricants, wetting agents, emulsifiers, suspending agents, binders, disintegrants, solvents, solubilizing agents, buffers, isotonicity agents, preservatives, flavoring agents, coloring agents, etc. may be appropriately added according to the needs of the formulation.
[0022] The symptom-relieving agent according to the present invention is preferably administered to humans or animals other than humans. Examples of animals other than humans include mammals such as cows, pigs, horses, sheep, goats, donkeys, monkeys, dogs, cats, rabbits, mice, rats, hamsters, and guinea pigs. The symptom-relieving agent according to the present invention is preferably administered to or ingested by humans, livestock, laboratory animals, and pets, and more preferably administered to or ingested by humans.
[0023] The dosage or intake amount of the symptom-relieving agent according to the present invention is appropriately selected and determined depending on the species, age (months), weight, symptoms, severity of disease, administration schedule, formulation form, etc. of the animal to be administered. For example, the daily dose per adult is 0.1 mg to 10 g, preferably 0.5 mg to 7 g, more preferably 10 mg to 5 g, and even more preferably 100 mg to 2 g, in terms of β-NMN, which can be administered once or in divided doses.
[0024] β-NMN is a biological component and is also contained in food, so it is considered to be highly safe. Therefore, the symptom-relieving agent of the present invention can be used as an active ingredient of a dietary supplement taken to relieve Parkinson's disease-like symptoms. Dietary supplements are foods and drinks that supplement nutrition for the purpose of maintaining or improving health, and include foods for specified health uses, foods with nutritional functions, and health foods. Since the symptom-relieving agent of the present invention is highly safe and suitable for long-term continuous intake, dietary supplements containing the symptom-relieving agent are expected to have excellent Parkinson's disease prevention and improvement effects.
[0025] In addition, the symptom-relieving agent according to the present invention can be used as an active ingredient in feed for animals to ingest in order to alleviate Parkinson's disease-like symptoms. By feeding the feed to livestock, pets, laboratory animals, etc., the function of mitochondria in the brain and muscle cells of the animals that have ingested the feed is improved, and as a result, it is expected that Parkinson's disease can be prevented and the pathology improved.
[0026] The dietary supplement and feed of the present invention can be produced by adding an appropriate auxiliary agent to β-NMN, etc., and then forming it into a form suitable for consumption, such as a powder, granule, tablet, capsule, soft capsule, paste, etc., using conventional means. The dietary supplement of the present invention may be consumed as it is, or may be consumed in a state of being mixed with various foods and beverages. For example, the powdered dietary supplement can be ingested in a state of being dissolved or dispersed in beverages such as water, alcoholic beverages, fruit juice, milk, and soft drinks. The feed of the present invention may also be ingested by animals as it is, or may be ingested by animals in a state of being mixed with other solid feed or drinking water.
[0027] The dietary supplement and feed according to the present invention may contain other food materials and various additives, such as vitamins, carbohydrates, proteins, lipids, dietary fiber, and fruit juice. Specific examples of such ingredients include vitamin B group ingredients such as vitamin B1 derivatives, vitamin B2, vitamin B6, vitamin B12, vitamin B13, biotin, pantothenic acid, nicotinic acid, and folic acid; fat-soluble vitamins such as vitamin E, vitamin D or its derivatives, vitamin K1, vitamin K2, and β-carotene; minerals such as calcium, potassium, iron, and zinc; yeast, L-carnitine, creatine, α-lipoic acid, glutathione, glucuronic acid, taurine, collagen, soy isoflavone, lecithin, peptides, amino acids, γ-aminobutyric acid, diacylglycerol, DHA, EPA, capsaicin, chondroitin sulfate, agaricus mushroom extract, carrot extract, garlic extract, green juice, lecithin, royal jelly, propolis, octacosanol, flavangenol, pycnogenol, maca, chitosan, Garcinia extract, chondroitin, and glucosamine. Examples of additives include sweeteners, acidulants such as organic acids, stabilizers, flavors, colorants, and the like. EXAMPLES
[0028] The present invention will now be described in more detail with reference to examples, but the present invention is not limited to the following examples.
[0029] [Example 1] After differentiating human neuroblastoma-derived SH-SY5Y cells, rotenone and β-NMN were added to the culture medium at concentrations of 100 μmol / L and 0, 5, 50, or 500 μmol / L, respectively, and the survival rate was evaluated two days later using an ATP measurement reagent. The results are shown in Figure 1. The survival rate increased concentration-dependently, confirming that the addition of β-NMN suppressed cell death caused by rotenone.
[0030] [Example 2] After differentiating human neuroblastoma-derived SH-SY5Y cells, the neurotoxins 6-hydroxydopamine (6-OHDA) and β-NMN were added to the culture medium at concentrations of 0 or 100 μmol / L and 0, 0.063, 0.125, 0.25, and 0.5 mmol / L, respectively, and the survival rate was evaluated using WST-1 reagent two days later. The measurement results are shown in Figure 2. Since there was no evidence of a concentration-dependent increase in survival rate, as was seen in Example 1, it was inferred that β-NMN suppresses cell death caused by mitochondrial function inhibition.
[0031] [Example 3] After differentiating SH-SY5Y cells derived from human neuroblastoma, rotenone, edaravone as a positive control, and β-NMN were added to the culture medium at concentrations of 0 or 50 μmol / L, 0 or 50 μmol / L, and 0 or 0.5 mmol / L, respectively, and the survival rate was evaluated using WST-1 reagent two days later. The measurement results are shown in Figure 3. Cell death was suppressed in the edaravone-added group, but was further suppressed in the β-NMN-added group, suggesting that β-NMN enhanced the effect of edaravone.
[0032] [Example 4] A β-NMN administration test was conducted using Parkinson's disease model rats as follows.
[0033] (Rat) Crl:CD(SD) rats used in the following experiments were kept in a specific-pathway environment throughout the entire experimental period. Solid feed (CRF-1, Oriental Yeast Co., Ltd.) and drinking water were available ad libitum throughout the entire experimental period.
[0034] (Oral administration) For oral administration, a solution of β-NMN (manufactured by Oriental Yeast Industry Co., Ltd.) dissolved in water for injection (manufactured by Otsuka Pharmaceutical Factory Co., Ltd.) was forcibly administered using a disposable polypropylene syringe (Terumo Corporation) attached to a disposable oral probe for rats (Fuchigami Instruments Co., Ltd.).
[0035] (Creation of a rat model of Parkinson's disease by intranigra injection of rotenone) After anesthetizing the rats, 1 μL of rotenone (12 μg / 1 μL) was injected into the substantia nigra on one side using a microsyringe pump (1 μL of DMSO was injected in the sham-operated group). After injection, the scalp was sutured.
[0036] (Coordination Test) A rotarod (MED ASSOCIATES INC.) was used for the coordination test, and the test was divided into training trials and measurement trials. Training trials were conducted twice a day for three days from the start of habituation. Furthermore, training trials were conducted twice a day for two days on days 12-13 and 26-27 of administration. The animals were placed on a rotor rotating at a constant speed (16 rpm) for three minutes and allowed to walk. Measurement trials were conducted 2 days after the end of the training trial during the habituation period, and on the 14th and 28th days after administration. Two trials were conducted per measurement. The animal was placed on a rotor that accelerated from 4 to 40 rpm, and the time it took for the animal to fall from the rotor (fall time: seconds) was measured. The measurement time was up to 5 minutes. In addition, the average fall time was calculated for each trial day. The calculated average fall time was used as an index of coordinated movement. The average was rounded off to one decimal place and displayed to one decimal place.
[0037] (Blood Test) Blood samples were collected from rats and centrifuged to separate blood cells and plasma. The blood cells were used to measure NAD concentration, and the plasma was used to measure creatine kinase activity.
[0038] The Parkinson's disease model rats were divided into three groups, eight rats per group: a group administered only water (non-administered group), a group administered rotenone (rotenone administration group), and a group administered rotenone and β-NMN (rotenone + NMN administration group) (Table 1). The NMN group was orally administered β-NMN once a day for a total of 28 days.
[0039] [Table 1]
[0040] (Results of measuring NAD content in blood cells) The nicotinamide adenine dinucleotide (NAD) content in blood cells of each rat was measured for 28 days from the start of administration. The measurement results are shown in Figure 4. It was found that the NAD concentration in blood cells decreased in the rotenone-administered group, but increased in the rotenone + NMN-administered group. These results confirmed that the amount of NAD in blood cells that decreased due to rotenone treatment was restored by β-NMN administration.
[0041] (Measurement results of coordinated movement) Coordination tests (training trials) were conducted for each rat on days 12-13 and 26-27 after the start of administration, and coordination tests (measurement trials) were conducted on days 14 and 28. The measurement results are shown in Figure 5. In the rotenone group, the time it took to fall from the rotor was shorter, indicating some kind of impairment in brain function and that the rats were unable to control their body movements well. In the rotenone + NMN group, the time it took to fall from the rotor was similar to that of the sham-operated group, confirming that administration of β-NMN had alleviated brain dysfunction.
[0042] (Correlation between NAD content in blood cells and coordinated movement measurement results) The correlation between the NAD content in blood cells and the results of the coordination test under rotenone administration conditions is shown in Figure 6. The correlation coefficient was 0.709, which was a fairly strong correlation, and it became clear that the higher the NAD content in blood cells, the better the results of the coordination test.
[0043] (Blood creatine kinase level measurement results) The decline in mitochondrial function in the brain caused by rotenone treatment leads to Parkinson's disease-like motor dysfunction as well as an increase in blood creatine levels. Therefore, blood was collected from the rats after the end of administration and the amount of creatine kinase in the plasma was measured. The measurement results are shown in Figure 7. The amount of creatine kinase in plasma increased in the rotenone-administered group, but decreased to the same level as the non-administered group in the rotenone + NMN-administered group. From these results, it was confirmed that the amount of creatine kinase in the blood was improved by administering β-NMN.
[0044] These results confirmed that mitochondrial dysfunction caused by rotenone treatment was improved by β-NMN administration. In other words, β-NMN was shown to be effective in alleviating Parkinson's disease-like symptoms, particularly Parkinson's disease-like motor dysfunction caused by mitochondrial dysfunction.
Claims
1. The present invention is characterized in that the active ingredient is one selected from β-nicotinamide mononucleotide, a pharmacologically acceptable salt thereof, and a solvate thereof. An agent for relieving Parkinson's disease-like symptoms accompanied by a decrease in NAD content in blood cells.
2. The symptom-relieving agent according to claim 1, which is administered orally.
3. The agent for relieving symptoms according to claim 1 or 2, which relieves Parkinson's disease-like motor dysfunction caused by reduced mitochondrial function.
4. A dietary supplement for alleviating Parkinson's disease-like symptoms, comprising the symptom-relieving agent according to any one of claims 1 to 3.
5. A feed for alleviating Parkinson's disease-like symptoms, comprising the symptom-alleviating agent according to any one of claims 1 to 3.
Citation Information
Patent Citations
Medical composition used for delaying development process of early parkinson's disease
CN111759876A
Methods and compositions for treating neurological disorders
JP2008501343A
Methods of Affecting Biological Function Through Circadian Clock Feedback Cycle by NAMPT-Mediated NAD+ Biosynthesis
US20110123510A1
Use of NADH and NMN in preparation of drugs or health-care products for treating parkinson's disease
US20170080011A1
Processes for regulating blood glucose in a mammal
US7737158B2
